Status:
COMPLETED
Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Lead Sponsor:
Stanford University
Conditions:
Substance-Related Disorders
Eligibility:
MALE
18-35 years
Phase:
NA
Brief Summary
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications ...
Detailed Description
We hope to learn if Palonosetron and/or combination with hydroxyzine can be used to prevent or attenuate the signs and symptoms of opioid withdrawal. If we find that it can help prevent these symptoms...
Eligibility Criteria
Inclusion
- Healthy males
- Ages 18-35
- No allergies to morphine or palonosetron
- No history of addiction or substance abuse
Exclusion
- Female
- Younger than 18 or older than 35
- History of substance abuse
- Raynaud's disease or coronary artery disease
- Allergies to morphine or palonosetron
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00661674
Start Date
April 1 2008
End Date
August 1 2008
Last Update
June 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305